Healthcare Industry News: oxytocin
News Release - August 10, 2015
Turing Pharmaceuticals Announces $90 Million Series A FinancingProceeds will be used to invest in developing treatments for serious diseases across a broad range of therapeutic areas
NEW YORK, Aug. 10, 2015 -- (Healthcare Sales & Marketing Network) -- Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer. One of the largest Series A rounds in biotech history, the financing included participation from multiple preeminent institutional equity investors and the simultaneous issuance of senior secured debt.
The company intends to invest the proceeds from the Series A financing in acquisitions as well as advancing and accelerating its growing pipeline of novel drug candidates.
"We are very happy with the institutional interest in our first capital raise. It's a great reflection on our business model and the collective track record of our leadership team developing breakthrough treatments for serious diseases," Mr. Shkreli said. "We plan to accelerate clinical trials for several treatments and are pleased to announce an immediate addition to our portfolio," he added. "We look forward to the continued execution of our plan to bring new treatments for serious diseases to patients, helping us maximize shareholder value."
Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in New York City and Zug, Switzerland. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Products being developed include intranasal ketamine for a variety of mood disorders and Syntocinon® (oxytocin nasal solution) for multiple indications. Vecamyl® (mecamylamine HCl tablets) for hypertension is Turing's first commercial product.
Source: Turing Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.